Recently, more SHIP2 selective inhibitors have been discovered as metformin (a FDA approved drug used in Type 2 diabetes) was recently shown to inhibit SHIP2 as well as the aforementioned Crizotinib derivatives like 23, which facilitates the evaluation of SHIP2 inhibitors for new therapeutic uses [172,192]. The gene discussed is INPPL1; the disease is type 2 diabetes mellitus.